HeartSciences, a Fierce Innovation Award Finalist, will present at Biotech Showcase Events in San Francisco on January 9 and 10, 2018

HeartSciences Logo

 

SOUTHLAKE, TEXAS – January 3, 2018 – HeartSciences, a medical device company recently selected as a finalist for the Fierce Innovation Awards in the Digital Health Solution category, will be presenting in San Francisco at the BioTech Showcase.  HeartSciences has two scheduled presentations: (1) Tuesday, January 9 at the BioTech Showcase at 2:45pm at the Hilton Hotel, Union Square and (2) Wednesday, January 10 at the Digital Medicine and Technology Showcase at 10.00am, at the Parc 55 Hotel.

 

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease.  Its MyoVista hsECG (high sensitivity ECG), is designed to significantly improve the sensitivity of a diagnostic electrocardiology device in detecting ischemic and structural heart disease at an early stage.  Through the patented use of Continuous Wavelet Transform digital signal processing it measures the heart’s energy during its cardiac cycle. Recent clinical trials demonstrate MyoVista’s ability to detect cardiac dysfunction in the diastolic phase, which is known as Diastolic Dysfunction. The MyoVista hsECG, includes all the conventional information of a full featured 12-lead resting ECG plus new energy related informatics assisting in the early detection of heart disease.

 

HeartSciences was selected as a Fierce Innovation Award Finalist in December 2017 for its innovative, MyoVista® hsECG™ (high sensitivity ECG) device. Finalists were selected from a highly competitive list of innovators by a distinguished panel of judges. All applications were evaluated based on the following criteria: Competitive Advantage, Financial Impact/Value, Market Need, and Overall Innovation. Applicants with the top 3 scores in each category were selected as finalists.  Life Sciences Edition 2017, is an awards program from the well-known e-publisher of FierceBiotech and FiercePharma.

 

About HeartSciences

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease.  HeartSciences is bridging today’s “diagnostic gap” in cardiac care by developing new low-cost effective solutions that assist in identifying at-risk patients.

 

HeartSciences’ MyoVista® hsECG™ Cardiac Testing Device is a new 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. It’s patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on abnormalities related to cardiac energy levels in addition to providing traditional ECG information.

 

In addition to the proprietary informatics, MyoVista hsECG also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms.

 

HeartSciences (formerly known as Heart Test Laboratories) is a privately-held U.S. corporation based in Southlake, Texas.

 

For more information visit www.heartsciences.com.

 

Corporate contact

Gene Gephart

+1 737 346 1089

gene.gephart@heartsciences.com

HeartSciences annuncia il lancio europeo di MyoVista

US-based medical device developer HeartSciences has launched its MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device in Europe after receiving CE-Mark.

MyoVista is intended to provide an effective, low-cost, front-line screening solution for cardiac disease in symptomatic as well as asymptomatic patients.

Click here for full story

EU launch for cardiac disease screening device

It’s no secret that both Apple and Google have their sights set on the healthcare market. Both have gradually become more involved with health-focused projects – the latter investing heavily in its life sciences division, Verily, and the former striking deals with health firms in its trademark covert fashion.

Click here for the full story

HeartSciences announces EU approval, launch of MyoVista hsECG

European regulators gave HeartSciences CE mark approval for its MyoVista high sensitivity electrocardiograph testing device, a technology that uses Continuous Wavelet Transform to measure cardiac energy per heartbeat. The device, which is a combination of traditional 12-lead resting ECG tracings, ECG interpretive analysis and informatics, has also been launched by the company in Europe.

Click here for the full story

HeartSciences wins CE mark, launches MyoVista ECG in the EU

HeartSciences said today that its MyoVista high sensitivity electrocardiograph testing device won CE Mark and launched in Europe.

The Westlake, Texas.-based company’s device measures the heart’s energy per heartbeat using Continuous Wavelet Transform, a type of advanced signal processing that provides doctors with a detailed visual description of a cardiac cycle’s energy distribution.

Click here for the full story

New advanced ECG tool for cardiac disease now available in Europe

European cardiologists may soon be able to detect the presence of heart disease more effectively in patients, thanks to a new advanced ECG tool.

HeartSciences’ MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device is now available for sale and distribution in markets across the European Union, following CE approval.

Click here for the story

HeartSciences gets green light to sell next-gen ECG in EU

HeartSciences has started selling its MyoVista electrocardiograph (ECG) in Europe after picking up a CE mark. The device is designed to enable early detection of artery disease by visualizing energy distribution during cardiac cycles.

Traditional ECGs detect and display the electrical signals the heart produces when it beats. The low cost and safety of the test made it a go-to option for doctors. But the shortcomings of ECGs have seen organizations including U.K. cost watchdog NICE recommend against their use in certain situations. ECGs are particularly poor at detecting structural and ischemic heart disease.

Click here for the full story

HeartSciences introduces the MyoVista® hsECG™ Cardiac Testing Device at the 2017 European Society of Cardiology

HeartSciences is a medical device company with the mission to enable accurate, affordable screening for the early detection of heart disease.  Our groundbreaking MyoVista® high-sensitivity ECG (hsECGTM) device advances the field of cardiac testing by filling the “diagnostic gap” in cardiac care and detecting cardiac dysfunction even in asymptomatic stages.